Drug-eluting stents: Cost versus clinical benefit

Circulation

Volumn 107, Issue 24, 2003, Pages 3003-3007

  Lemos, Pedro A ^a   Serruys, Patrick W ^a   Sousa, J Eduardo ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; RAPAMYCIN;

COST BENEFIT ANALYSIS; IMPLANTATION; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; RISK BENEFIT ANALYSIS; SHORT SURVEY; STENT;

BLOOD VESSEL PROSTHESIS IMPLANTATION; CLINICAL TRIALS; CORONARY RESTENOSIS; COST-BENEFIT ANALYSIS; DRUG IMPLANTS; HUMANS; STENTS; TREATMENT OUTCOME;

EID: 0037805772     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000078025.19258.28     Document Type: Short Survey

References (23)

1. Sousa JE, Costa MA, Abizaid A, et al. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2001;103:192-195.
2. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
3. de Scheerder I, Gershlick A, Chevalier B, et al. The Elutes Clinical Study: 12-month clinical follow-up. Circulation. 2002;106(suppl II):II-394. Abstract.
4. Park SJ, Shim WH, Ho D, et al. A paclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 2003;348:1537-1545.
5. Leon MB, Moses JW, Popma JJ, et al. A multicenter randomized clinical study of the sirolimus-eluting stent in native coronary lesions: angiographic results. Circulation. 2002;106(suppl II):II-393. Abstract.
6. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: part II. Circulation. 2003;107:2383-2389.
7. Sousa JE, Abizaid A, Abizaid AS, et al. First clinical experience with 17-β estradiol-eluting Biodivysiomatrix LO stent to prevent restenosis in de novo native coronary arteries: early clinical outcomes and angiographic follow-up from the Easter Trial. Circulation. 2002;106(suppl II):II-393. Abstract.
8. Doucet S, Malekianpour M, Theroux P, et al. Randomized trial comparing intravenous nitroglycerin and heparin for treatment of unstable angina secondary to restenosis after coronary artery angioplasty. Circulation. 2000;101:955-961.
9. Serruys PW, Unger F, Sousa JE, et al. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med. 2001;344:1117-1124.
10. Degertekin M, Serruys PW, Foley DP, et al. Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation. 2002;106:1610-1613.
11. Regar E, Serruys PW, Bode C, et al. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation. 2002;106:1949-1956.
12. Sousa JE, Costa MA, Abizaid A, et al. Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation. 2003;107:24-27.
13. Degertekin M, Regar E, Tanabe K, et al. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol. 2003;41:184-189.
14. Grube E, Silber S, Hauptmann KE, et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation. 2003;107:38-42.
15. Liistro F, Stankovic G, Di Mario C, et al. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation. 2002;105:1883-1886.
16. Virmani R, Liistro F, Stankovic G, et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation. 2002;106:2649-2651.
17. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: part II. Circulation. 2002;106:2859-2866.
18. Sousa JE, Abizaid A, Abizaid A, et al. Late (three-year) follow-up from the first-in-man (FIM) experience after implantation of sirolimus-eluting stents. Circulation. 2002;106(suppl II):II-394. Abstract.
19. Schwartz L, Kip KE, Frye RL, et al. Coronary bypass graft patency in patients with diabetes in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 2002;106:2652-2658.
20. Lemos PA, Lee CH, Degertekin M, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol. 2003;41:2093-2099.
21. Serruys PW, Degertekin M, Tanabe K, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation. 2002;106:798-803.
22. Serruys PW, van Hout B, Bonnier H, et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 1998;352:673-681.
23. van den Brand M, van Halem C, van den Brink F, et al. Comparison of costs of percutaneous transluminal coronary angioplasty and coronary bypass surgery for patients with angina pectoris. Eur Heart J. 1990;11:765-771.